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Abstract: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin has been successful 
in reducing ischemic events in a wide range of patients with cardiovascular diseases. However, 
the anti-ischemic effects of DAPT may also be associated with gastrointestinal (GI) complica-
tions including ulceration and bleeding particularly in ‘high risk’ and elderly patients. Current 
guidelines recommend the use of proton-pump inhibitors (PPIs) to reduce the risk of GI bleeding 
in patients treated with DAPT. However, pharmacodynamic studies suggest an effect of PPIs 
on clopidogrel metabolism with a resultant reduction in platelet inhibitory effects.   Similarly, 
several observational studies have demonstrated reduced clopidogrel benefit in patients who coad-
ministered PPIs. Although recent US Food and Drug Administration and European Medicines 
Agency statements discourage PPI (particularly omeprazole) and clopidogrel coadministration, 
the 2009 AHA/ACC/SCAI PCI guidelines do not support a change in current practice in the 
absence of adequately powered prospective randomized clinical trial data. The data regard-
ing pharmacologic and clinical interactions between PPI and clopidogrel therapies are herein 
examined and treatment strategies are provided.
Keywords: cardiovascular disease, gastrointestinal, proton-pump inhibitor, antiplatelet 
therapy
Introduction
Platelet activation and reactivity play an important role in the occurrence of ischemic 
events during acute coronary syndromes (ACS) and following percutaneous inter-
vention (PCI). The two important secondary agonists, thromboxane and particularly 
adenosine diphosphate (ADP) are released upon platelet activation and are responsible 
for the sustained platelet activation and aggregation and the generation of subsequent 
thrombus at the site of vascular injury. Therefore, inhibition of these two major path-
ways, thromboxane synthesis by aspirin and ADP (P2Y12) receptor activation by P2Y12 
receptor blockers constitutes a major strategy to attenuate ischemic events. Moreover, 
this strategy has been shown to be effective in attenuating atherothrombotic events 
across a wide range of patients with cardiovascular disease.1 However, the benefit of 
antiplatelet therapy may be associated with gastrointestinal (GI) complications includ-
ing ulceration and bleeding.2 Current guidelines recommend the use of proton pump 
inhibitors (PPIs) to reduce the risk of gastrointestinal bleeding (GIB) in patients treated 
with dual antiplatelet therapy (DAPT). However, pharmacodynamic studies suggest 
an effect of PPIs on clopidogrel metabolism with a resultant reduction in platelet 
inhibitory effects. Similarly, several observational studies have demonstrated reduced 
clopidogrel benefit in patients who coadministered PPIs. Although recent US Food and Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Drug Administration (FDA) and European Medicines Agency 
(EMEA) statements discourage PPI (particularly omeprazole) 
and clopidogrel coadministration, the 2009 American Heart 
Association/American College of Cardiology/Society for 
Cardiac Angiography and Interventions (AHA/ACC/SCAI) 
PCI guidelines do not support a change in current practice in 
the absence of adequately powered prospective randomized 
clinical trial data. The data regarding pharmacologic and 
clinical interactions between PPI and clopidogrel therapies 
are herein examined and treatment strategies are provided.
Rationale for coadministration  
of clopidogrel and PPIs
Prostaglandins, especially prostaglandin E2 (PGE2) and throm-
boxane A2, are involved in the regulation of gastric mucosal 
blood flow, stimulation of mucosal and bicarbonate secretions, 
and the proliferation of gastric epithelial cells. Thus, inhibition 
of prostaglandin synthesis by aspirin may impair the protec-
tive barrier for gastric mucosa making it more susceptible to 
ulceration induced by endogenous acid, pepsin, and bile salts. 
In addition, inhibition of platelet aggregation along with vari-
ous growth factors released from activated platelets at the site 
of vascular injury during aspirin therapy can attenuate gastric 
healing and increase susceptibility to GIB.3
A meta-analysis of five randomized clinical trials demon-
strated that combination therapy with aspirin plus clopidogrel 
is associated with reductions in all-cause and cardiovascular 
mortality in patients who present with ST-segment elevation 
myocardial infarction (STEMI) as well as modest reduc-
tions in myocardial infarction (MI) or stroke in patients 
with symptomatic cardiovascular disease.4 DAPT was also 
associated with an overall increase in the incidence of major 
bleeding events (1.6% versus 1.3%, odds ratio [OR] 1.26; 
95% confidence interval [CI]: 1.211–1.41; P , 0.0001) but 
not fatal bleeding or hemorrhagic stroke.4 Although clopi-
dogrel lacks direct ulcerogenic effects, the platelet inhibition 
by clopidogrel may attenuate healing of existing gastric 
ulcerations and may augment risk for GIB. In the CAPRIE 
trial, therapy with aspirin alone (325 mg/day) increased risk 
for major GIB (relative risk [RR] 1.45; 95% CI: 1.00–2.10) 
compared to clopidogrel monotherapy (75 mg/day).5   
In the CURE trial, aspirin monotherapy was associated with 
less frequent major GIB when compared to therapy with 
aspirin plus clopidogrel (RR 0.56; 95% CI: 0.39–0.80). In the 
MATCH trial, clopidogrel monotherapy was associated with 
less frequent major GIB compared to combination clopidogrel 
plus aspirin treatment (RR 0.34; 95% CI: 0.23–0.51).6,7 In a 
Danish case-control study, GIB was observed more frequently 
in patients treated with low-dose aspirin alone (OR 1.8; 95% 
CI: 1.5–2.1) compared to age- and sex-matched controls, and 
the greatest risk was observed in patients receiving DAPT 
when compared to age- and sex-matched controls (OR 7.4; 
95% CI: 3.5–15).8 In the CHARISMA trial, an increased risk 
of GUSTO bleeding (mostly GIB) was observed during long-
term DAPT compared with aspirin monotherapy. Interestingly, 
the relative risk of bleeding on DAPT was greatest during 
the first year of therapy.9 Furthermore, the relative risk of GI 
complications observed during DAPT compared with aspirin 
monotherapy was increased two- to threefold in randomized 
clinical trials and sevenfold in observational studies.8–11   
In addition to DAPT, other factors such as older age, male 
sex, advanced heart failure symptoms, and diabetes were 
independently   associated with GIB. Finally, a history of prior 
ulcer   disease as well as concomitant therapy with NSAID, 
anticoagulants, and/or aspirin has been associated with an 
increased risk of GIB in clopidogrel-treated patients.11,12
The occurrence of GIB is associated with morbidity and 
mortality in patients with underlying cardiovascular disease 
and following PCI.9,11 A correlation between the occurrence 
of major bleeding events and subsequent MI, stroke, or death 
was observed in both the OASIS and CURE trials.13 In the 
CHARISMA trial, moderate severity bleeding events were 
associated with all-cause mortality (hazard ratio [HR] 2.92; 
95% CI: 1.71–3.80; P , 0.001), MI (HR 2.92; 95% CI: 2.04–
4.18; P , 0.001), and stroke (HR 4.20; 95% CI: 3.05–5.77; 
P , 0.001), and the occurrence of GIB was associated with 
all-cause mortality (HR 1.82; 95% CI: 1.24–2.69).9 Similarly, 
a multivariate analysis of the ACUITY trial demonstrated that 
GIB was associated with all-cause mortality, cardiac mortality, 
and a composite ischemic endpoint to both 30 days and 1 year 
as well as with stent thrombosis to 1 year. GIB was the most 
frequent cause of bleeding in medically managed patients and 
the second most frequent cause of non-CABG-related bleeding 
(following access site bleeding) in the entire study popula-
tion. Finally, GIB was an important correlate of premature 
antiplatelet therapy cessation, and 20.8% of GIB patients were 
discharged without aspirin or thienopyridine therapy.14
Obviously, a balance between cardiovascular risk 
(the major rationale for DAPT) and risk for GIB must be 
  established. Current guidelines recommend uninterrupted 
DAPT for ‘at least 1 year’ in patients presenting with ACS 
and/or those treated with drug-eluting stents. Multiple data 
sources provide a rationale for the concomitant adminis-
tration of PPIs in patients treated with either aspirin alone 
or with DAPT especially those at greatest risk for GIB 
complications. Lanas et al demonstrated that the addition of a Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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PPI (omeprazole, lansoprazole, pantoprazole, rabeprazole, or 
esomeprazole) to either aspirin or thienopyridine therapy was 
associated with a reduction in the risk of GIB compared with no 
PPI treatment (RR = 0.32 and 0.19 for aspirin and thienopyri-
dine, respectively).15 In addition, it has been demonstrated 
that a prior history of GIB predicts risk for subsequent GIB 
in clopidogrel-treated patients.16 Indeed, the history of peptic 
ulcer disease was an independent predictor of risk for GIB in 
patients treated with DAPT, and the concomitant administra-
tion of PPI reduced GIB risk.17 Several studies suggest that 
PPIs may neutralize the risk of GIB in aspirin-treated patients. 
For example, clopidogrel monotherapy (no PPI) was associated 
with a higher incidence of recurrent ulcer bleeding than therapy 
with aspirin plus esomeprazole (8.6% versus 0.7%; 95% CI: 
3.4–12.4) in patients who were Helicobacter pylori-negative 
and who had a history of GIB on low-dose aspirin therapy.18 
Peptic ulceration was more frequently observed following 
clopidogrel treatment than following aspirin–esomeprazole 
combination (13.6% versus 0%, respectively; P = 0.002).16 In 
a recent population-based study of patients with a history of 
major GI complications, those who were treated with aspirin 
plus PPI were less frequently hospitalized for recurrent GI 
complications than were those treated with aspirin alone 
(HR 0.76; 95% CI: 0.64–0.91). Interestingly, patients treated 
with PPI plus clopidogrel experienced a similar risk of major 
GI complications (HR 1.08; 95% CI: 0.89–1.33) compared 
with those receiving clopidogrel alone.19 These observations 
suggest that the administration of PPI as a gastroprotective 
agent in patients treated with either aspirin or DAPT can 
mitigate the risk of GIB.
Both clopidogrel and PPIs are among the most widely pre-
scribed medications with worldwide sales in 2008 of $8.6 and 
$26.5 billion, respectively.20 Furthermore, thienopyridine–
PPI coadministration is frequent and occurred in 31% of 
subjects in the CREDO trial, 33% in TRITON–TIMI 38, 54% 
in PLATO (clopidogrel arm), and 64% in the Veterans Affairs 
(VA) retrospective analysis study. Among these studies, the 
most commonly administered PPI was omeprazole, which 
accounted for 60% of PPI use in the VA retrospective study 
and 37% in TRITON–TIMI 38 study.21–23 Therefore, based 
on the prevalence of use and high frequency of concomitant 
PPI–thienopyridine administration, any pharmacokinetic/
pharmacodynamic interaction between these agents which 
could influence clinical efficacy and safety must be carefully 
and thoroughly evaluated. On the basis of available data, the 
US FDA, EMEA, and ACC/AHA guidelines have provided 
conflicting recommendations with regard to the concomitant 
use of PPIs and clopidogrel.2,24–28
Clopidogrel metabolism
Clopidogrel is administered orally as a prodrug and only 
10%–15% of absorbed clopidogrel is available for hepatic con-
version to an active metabolite in a two-step process. Metabolic 
conversion occurs rapidly and neither native clopidogrel nor 
active metabolites are detectable in plasma beyond 2 h follow-
ing oral clopidogrel administration. Recent studies suggest 
that hepatic cytochrome P450 (CYP) isoenzymes CYP2C19, 
CYP1A2, and CYP2B6 are responsible for the first step of 
metabolic conversion, whereas CYP2C19, CYP2C9, CYP2B6, 
and CYP3A4 are responsible for the second step. CYP2C19 
contributes prominently to both steps and CYP3A4 substan-
tially to the second step. Clopidogrel therapy is associated with 
a wide response variability/nonresponsiveness that is mostly 
attributed to variable/insufficient active metabolite generation. 
  Variability in intestinal absorption, drug–drug interactions 
at the CYP isoenzyme level, and genetic polymorphisms of 
CYP isoenzymes (particularly CYP2C19*2) which lead to 
CYP functional variability are major contributors to variabil-
ity in clopidogrel response. A diminished pharmacodynamic 
response (inhibition of platelet aggregation) to clopidogrel has 
been observed following coadministration of PPIs, lipophilic 
statins, calcium channel blockers, and warfarin which are 
metabolized by the CYP2C19, CYP3A4, and CYP2C9 
isoenzymes.29,30 Importantly, clopidogrel nonresponsiveness or 
high ‘on-treatment’ platelet reactivity has been correlated with 
adverse ischemic events in multiple independent studies.30
Metabolism of PPIs
PPIs (with the exception of rabeprazole) are absorbed 
efficiently and metabolized rapidly by CYP isoenzymes, 
especially CYP2C19 and CYP3A4. Although PPIs differ 
with regard to pharmacokinetic and pharmacodynamic 
properties, they are equally potent in inhibiting gastric secre-
tion when administered with proper dosing. In addition to 
being metabolized by CYP isoenzymes, PPIs (similar to 
clopidogrel) also competitively inhibit CYP2C9, CYP2D6, 
CYP3A4, and particularly CYP2C19. The half-life of PPIs 
is 1–2 h. PPIs may affect the metabolism of other drugs 
metabolized by CYP2C19 such as diazepam, phenytoin, 
and R-warfarin. The magnitude of PPI inhibitory effect 
(particularly omeprazole) on the metabolism of other drugs 
is more pronounced in extensive metabolizers of 2C19 
isoenzyme with gain-of-function allele (2C19*17) compared 
to poor metabolizers with 2C19 loss-of-function allele 
(2C19*2). Furthermore, metabolism of omeprazole may 
shift to CYP3A4 from CYP2C19 in poor metabolizers.31,32 In 
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PPIs, genetic   polymorphisms of both CYP2C19 as well as 
the ABCB1 gene may be responsible for a differential phar-
macokinetic/pharmacodynamic response to both PPIs as well 
as clopidogrel. The latter mechanisms may thus influence 
clinical outcomes related to acid suppression, H. pylori 
eradication, and the mitigation of ischemic events associated 
with PPIs and clopidogrel therapy, respectively.30,32
Pharmacodynamic interaction 
between clopidogrel and PPIs
As omeprazole is the most frequently prescribed PPI, the 
pharmacodynamic interaction between omeprazole and 
clopidogrel has been most extensively characterized. For 
example, vasodilator-stimulated phosphoprotein (VASP)-
phosphorylation levels (a direct reflection of P2Y12 receptor 
activity) were significantly increased after at least 48 h fol-
lowing the addition of PPI in subjects treated with aspirin 
and clopidogrel compared with those receiving aspirin and 
clopidogrel alone (P = 0.007). Similarly, in a randomized, 
double-blind, placebo-controlled study, the concomitant 
administration of omeprazole with clopidogrel significantly 
increased the VASP-phosphorylation index (51.4% versus 
39.8% placebo, P , 0.0001) at day 7 of therapy but not on 
day 1. This observation suggests that the effect of omeprazole 
to reduce the level of clopidogrel active metabolite and thus 
clopidogrel-mediated platelet inhibition is dynamic over 
time.33,34 A variable effect of lansoprazole on platelet inhibi-
tion by prasugrel or clopidogrel and on the active metabolite 
generation of both thienopyridines has been described.35 
In a post-hoc subgroup analysis of the PRINCIPLE-TMI 
44 study, the coadministration of PPI with either clopidogrel 
or prasugrel was associated with reduced inhibition of platelet 
aggregation measured early and late (15 days) on treatment. 
This observation suggests that PPIs are effective in reducing 
the level of active metabolite   generation for both clopidogrel 
and prasugrel.36
Differences between PPIs with regard to their influence 
on antiplatelet effect of clopidogrel may exist. For example, 
in a cross-sectional study of patients (n = 1000) scheduled for 
PCI, significantly higher levels of on-treatment ADP-induced 
platelet aggregation (using Multiplate® analyzer, Munich, 
Germany) were observed in patients receiving omeprazole 
(mean AU*min = 295, P = 0.001), but not pantoprazole 
or esomeprazole (mean range = 134–226 AU*min) when 
compared to patients not receiving PPI in conjunction with 
clopidogrel therapy (mean = 220 AU*min). In addition, the 
prevalence of low responders to clopidogrel (.456 AU*min, 
upper quintile) was significantly higher   following omeprazole 
treatment (33% versus 19%, P = 0.008).37 However, in 
another study of patients (n = 1425) undergoing PCI, 
on-treatment platelet aggregation (∼20 h after a 600-mg 
clopidogrel oral loading dose) was significantly higher in 
patients receiving concomitant PPI (similar for omeprazole, 
esomeprazole, and pantoprazole) compared to patients not 
treated with PPI (P , 0.001).38 In additional, nonrandom-
ized analysis of 300 patients undergoing PCI following a 
600-mg oral clopidogrel loading dose, no apparent interac-
tion between pantoprazole or esomeprazole with clopidogrel 
with regard to platelet inhibition was observed.39 Similarly, 
Cuisset et al demonstrated a better antiplatelet effect of 
clopidogrel following pantoprazole as measured by the 
VASP-phosphorylation assay (but not ADP-induced platelet 
aggregation) in a randomized comparison with omeprazole 
among 104 patients undergoing stenting for NSTE ACS 
who were treated with DAPT of 150-mg clopidogrel plus 
75-mg aspirin.40
In summary, the major site of drug–drug interac-
tion between clopidogrel and PPIs appears to involve the 
CYP2C19 isoenzyme pathway. Although the PK/PD interac-
tion between clopidogrel and PPIs has not been demonstrated 
to significantly influence the clinical efficacy of either drug, 
coadministration of omeprazole with clopidogrel was demon-
strated to decrease (up to 20%) clopidogrel-mediated platelet 
inhibition. This effect was more pronounced at 7–14 days 
compared with 1 day of treatment after a clopidogrel load-
ing dose and translated into both an increased prevalence 
of clopidogrel nonresponders as well as more patients 
with ‘high on-treatment platelet reactivity’, an established 
cardiovascular risk factor. Among these studies, the abso-
lute decrease in clopidogrel-mediated platelet inhibition 
attributable to PPIs was in the magnitude of 20% by light 
transmission aggregometry 41–76 PRU by VerifyNow P2Y12 
assay, ∼95 units AU*min by Multiplate analyzer and up to 
12% by VASP-P PRI. These results were associated with a 
significant increase in the prevalence of ‘nonresponders’ as 
defined by the respective assay.
Influence of coadministration of PPI 
with clopidogrel on clinical outcome
Numerous observational studies and meta-analyses have 
suggested an influence of PPI coadministration on the clini-
cal efficacy of clopidogrel. Although these studies reflect the 
real-world scenario, these studies are associated with inherent 
deficiencies such as selection bias, variable effects of various 
comedications, compliance, and so on. A retrospective insur-
ance claim-based study reported that rates of MI to 1 year Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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were significantly higher in clopidogrel-treated patients who 
had high PPI exposure compared with those having either 
low PPI exposure or treated with clopidogrel alone (5.03%, 
3.08%, and 1.38%, respectively, P , 0.05).34,41 In the MEDCO 
Outcomes study among patients, a higher incidence of major 
CV events (hospitalization for stroke, MI, angina, or CABG) 
was observed to 1 year following coronary stent deployment 
in patients taking concomitant PPI versus those who were not 
(32.5% versus 21.2%, adjusted OR 1.79; 95% CI: 1.62–1.07). 
This difference remained significant even after adjusting for 
baseline differences in age, gender, and measured comor-
bidities.42 Conversely, the primary outcome measurement at 
28 days (death/MI/urgent target vessel revascularization) and 
1 year (death/MI/stroke) was increased in those patients who 
were treated with PPIs at baseline, regardless of subsequent 
clopidogrel treatment strategy in a retrospective analysis of 
the CREDO trial.   Furthermore, treatment with clopidogrel 
reduced cardiovascular events at 1 year to a similar degree 
whether or not patients were receiving concomitant PPI.43
In an epidemiologic case-control study, the concurrent 
use of PPIs with clopidogrel was associated with recurrent 
MI (adjusted OR 1.27; 95% CI: 1.03–1.57) after multivariate 
adjustment among 13,636 patients who filled prescriptions for 
clopidogrel within 3 days of hospital discharge following acute 
MI. In this study, although pantoprazole (a relatively weak 
inhibitor of CYP2C19) was not associated with increased 
risk (OR 1.02; 95% CI: 0.70–1.47), other PPIs (omeprazole, 
lansoprazole, and rabeprazole) were collectively associated 
with a 40%-relative increase in risk of recurrent MI (OR 1.40; 
95% CI: 1.10–1.77) compared to no PPI treatment. These 
authors estimated that about 14% of all recurrent MI could be 
attributed to a clopidogrel–PPI interaction.44 In a retrospective 
analysis of 8205 ACS patients discharged from hospital on 
clopidogrel treatment (64% treated with PPIs), the addition 
of PPI to clopidogrel therapy was associated with increased 
risks for death or rehospitalization (adjusted OR 1.25; 95% 
CI: 1.11–1.41), hospitalization for recurrent ACS (adjusted 
OR 1.86; 95% CI: 1.57–2.20), and revascularization (adjusted 
OR 1.49; 95% CI: 1.30–1.71) compared with clopidogrel 
alone. Interestingly, all-cause mortality did not differ by PPI 
treatment.45 In a post-hoc analysis of the TRITON–TIMI 
38 study, no relation between PPI use and primary endpoint 
events was evident among patients treated with either clopi-
dogrel or prasugrel. However, PPI therapy was not randomly 
assigned and could have been initiated or discontinued during 
follow-up, as compliance records were lacking.36
In the COGENT (Clopidogrel and the Optimization 
of Gastrointestinal Events) study, 3672 patients (from an 
originally protected 5000 patient study population) who 
required clopidogrel therapy following non-STEMI, STEMI, 
or coronary stent implantation were randomly assigned to 
receive CGT-2168 (75-mg clopidogrel + 20-mg omeprazole) 
or 75-mg clopidogrel. The primary outcome measure of clini-
cally significant GI events after 362 days of follow-up (mean 
133 days) was significantly lower following combination 
therapy compared to clopidogrel monotherapy (38 events 
versus 67 events; P = 0.007). The secondary outcome 
measure of all cardiovascular events (composite of cardiac 
death, nonfatal MI, CABG, PCI, or ischemic stroke) and the 
individual endpoints of MI or revascularization were similar 
between randomly assigned treatments. These results suggest 
that there is no clinically relevant adverse interaction between 
clopidogrel and PPI treatment despite the results of ex vivo 
platelet function studies as well as observational clinical 
  studies. However, numerous limitations to the COGENT 
study have been noted and include premature study termi-
nation (for financial reasons), the poorly characterized anti-
platelet effect of the study drug (combination omeprazole + 
  clopidogrel), the exclusion of high risk and older patients, and 
a low-cardiovascular event rate (only 3.75%; 136 events/3627 
patients) compared to a ∼10% event rate in recent randomized 
trials such as PLATO and TRITON–TIMI 38.22,23,46
Finally, in a retrospective analysis of 18,565 patients who 
had either undergone PCI or been hospitalized for ACS and 
were subsequently treated with clopidogrel, the   addition of 
PPI to clopidogrel was associated with an increased risk 
of MI or death (OR 1.22; 95% CI: 0.99–1.51): death (OR 
1.20; 95% CI: 0.84–1.70) and revascularization (OR 0.97; 
95% CI: 0.79–1.21) compared with clopidogrel alone. On 
the basis of this propensity-score adjusted rate ratio analysis, 
the authors suggest that the clopidogrel–PPI interaction does 
not have major clinical relevance and that the increased risk 
of recurrent ischemic events attributable to an interaction 
does not exceed 20%.47
Significant heterogeneity in the risk of cardiovascular 
outcomes including MI was observed in a meta-analysis of 
23 studies involving 93,278 patients receiving clopidogrel 
with or without concomitant PPI which suggests that the 
data are inconsistent and/or confounded. Moreover, no 
measurable association was observed in the analysis of 
propensity-matched and/or randomized trial participants, 
whereas the observational studies more often demonstrated 
an association.48 Furthermore, the effect of clopidogrel 
and PPI interaction on clinical outcome measures steadily 
diminished from risk ratios observed in crude raw data to 
observational studies that adjusted for confounders and then Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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to randomized trials or propensity-matched studies. Indeed, 
recent studies demonstrated an elevated risk of adverse car-
diovascular outcomes with PPI alone compared to no PPI in 
the absence of concomitant clopidogrel therapy indicating 
a potentially harmful effect of PPI (adjusted risk ratios 1.55 
and 1.38).43,49,50
Finally, two recent retrospective studies suggest that pan-
toprazole may influence the clinical efficacy of   clopidogrel. 
In one study in which 64% of clopidogrel-treated patients 
were coadministered with pantoprazole, an increased risk 
of rehospitalization for MI or coronary stent placement 
(adjusted HR 1.91; 95% CI: 1.19–3.06; P = 0.008) was 
observed in pantoprazole-treated patients.49 In the other 
study, although concomitant use of PPIs (62% pantoprazole) 
with clopidogrel was associated with 50% fewer hospital-
izations for GIB compared with patients not treated with 
PPIs, the 95% CI for risk of cardiovascular events attribut-
able to PPI included the potential for clinically important 
increased risk.50
Treatment strategies
Small pharmacodynamic studies have indicated a poten-
tial influence of PPIs on antiplatelet effects of clopidogrel 
whereas retrospective, observational, and also meta-analyses 
indicated that influence of PPIs comedication on clinical 
benefits of clopidogrel may be present only in high-risk 
patients and may be more pronounced in patients treated 
with CYP2C19-metabolized PPIs such as omeprazole. 
Therefore, alternative strategies may be considered in high-
risk patients. In the contexts that PPIs have equal efficacy 
for gastric acid suppression with appropriate dosing and 
that the PK/PD interaction with clopidogrel is in large part 
mediated by hepatic CYP-450 isoenzymes (CYP2C19 and 
CYP3A4), rabeprazole (not CYP metabolized) may be a 
reasonable alternative for omeprazole. Another option may 
be to increase the maintenance dose of clopidogrel dur-
ing long-term therapy although the safety and efficacy of 
dose escalation have not been established. Moreover, in the 
PRINCIPLE TIMI 44 study, a significant pharmacodynamic 
interaction between clopidogrel (150 mg/day) and PPI36 was 
demonstrated on day 14 of treatment. Similarly, a significant 
interaction between PPIs and prasugrel (a third-generation 
thienopyridine) was observed through 14 days of maintenance 
dose (10 mg/day) treatment. As the plasma half-lives of both 
clopidogrel and omeprazole are short (1–2 h), the potential 
for drug–drug competition at either the P-glycoprotein or 
CYP2C19 level may be attenuated by separating the timing 
of clopidogrel and omeprazole administration. However, as 
omeprazole bioavailability is increased by repeated dosing 
(maximum at 5 days), such a ‘dose separation’ strategy may 
have diminishing advantage during the chronic coadministra-
tion of clopidogrel and omeprazole. Furthermore, the FDA 
statement mentions that dose separation does not prevent the 
interaction between omeprazole and clopidogrel. This state-
ment was based on data from crossover study of 72 healthy 
volunteers treated with clopidogrel (300-mg load followed 
by 75 mg/day for 5 days) and coadministered omeprazole 
(80 mg/day). The coadministration of omeprazole either with 
clopidogrel or 12 h apart from clopidogrel resulted in the 
same decrease in clopidogrel active metabolite and the same 
decrease in platelet inhibition by clopidogrel at both 24 h and 
5 days. However, it should be noted that the clopidogrel load-
ing dose of 300 mg is associated with insufficient/  variable 
active metabolite generation as well as widely variable anti-
platelet response, and the omeprazole dose of 80 mg/day is 
significantly higher than commonly prescribed daily doses 
of 20–40 mg/day.25 These facts raise questions regarding 
the validity of the study which forms the basis of the FDA 
statement which also recommends use of alternatives to PPIs 
such as H2 receptor blockers and antacids.25 Finally, a non-
thienopyridine, ticagrelor currently in clinical trial evaluation, 
does not require metabolic conversion by hepatic CYP-450 
isoenzymes and is not influenced by genetic polymorphisms 
or known drug–drug interactions. Thus, ticagrelor (not yet 
US FDA approved) may offer an effective alternative strat-
egy for P2Y12 receptor inhibition. Large-scale prospective 
randomized clinical trials are needed to demonstrate safety 
and efficacy of alternative strategies to address the potential 
interaction between clopidogrel and PPIs.
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